Description:
Discover the groundbreaking real-world study on Pembrolizumab for non-small cell lung cancer (NSCLC)! With a 5-year survival rate of 26.9%, this treatment is changing the game for NSCLC patients. Learn how factors like PD-L1 expression, age, and ECOG-
https://mdnewsline.com/five-year-survival-in-nsclc-patients-tre